Grossi, Francesco; Jaskiewicz, Piotr; Ferreira, Marion; Czyzewicz, Grzegorz; Kowalski, Dariusz; Ciuffreda, Libero; Garcia-gomez, Ramon; Caruso, Salvatore; Bosch-barrera, Joaquim; Gautier, Stephanie; Castro Junior, Gilberto de Castro 
Fonte: Therapeutic advances in medical oncology. Unidade: FM
Assuntos: ESTUDOS PROSPECTIVOS, NEOPLASIAS PULMONARES (TERAPIA), SOBREVIVÊNCIA LIVRE DE DOENÇA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GROSSI, Francesco et al. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). Therapeutic advances in medical oncology, v. 13, 2021Tradução . . Disponível em: https://doi.org/10.1177/17588359211022905. Acesso em: 22 ago. 2024.APA
Grossi, F., Jaskiewicz, P., Ferreira, M., Czyzewicz, G., Kowalski, D., Ciuffreda, L., et al. (2021). Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). Therapeutic advances in medical oncology, 13. doi:10.1177/17588359211022905NLM
Grossi F, Jaskiewicz P, Ferreira M, Czyzewicz G, Kowalski D, Ciuffreda L, Garcia-gomez R, Caruso S, Bosch-barrera J, Gautier S, Castro Junior G de C. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03) [Internet]. Therapeutic advances in medical oncology. 2021 ; 13[citado 2024 ago. 22 ] Available from: https://doi.org/10.1177/17588359211022905Vancouver
Grossi F, Jaskiewicz P, Ferreira M, Czyzewicz G, Kowalski D, Ciuffreda L, Garcia-gomez R, Caruso S, Bosch-barrera J, Gautier S, Castro Junior G de C. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03) [Internet]. Therapeutic advances in medical oncology. 2021 ; 13[citado 2024 ago. 22 ] Available from: https://doi.org/10.1177/17588359211022905
